5 Reasons to attend (online):
1. Navigate the oncology stakeholder ecosystem & how medical affairs can add value
2. Benchmark with leading experts on oncology KOL engagement, stakeholder communication, collaboration and insight generation
3. Understand the capabilities required to achieve for medical affairs effectiveness in oncology
4. Appreciate what do cancer stakeholders (patients, payers, cancer hospitals, physicians) specifically need?
5. Learn how to develop advanced real-world and clinical evidence to develop high-value therapies
Chief Medical Officer & Head of Global Medical Affairs
Eisai
Head of Medical Affairs Oncology Region Europe
Novartis, Switzerland
Senior Vice President, Head of Medical Affairs
Alkermes
Senior Director, Patient Health Activation Expert
Worldwide Medical and Safety | Global Medical Impact Assessment
Pfizer, USA
Senior Director, Global Medical Science Liaison
Philips Healthcare, USA
Head of Medical Affairs
Servier, Hungary
Director of Public Policy
The European Society for Medical Oncology (ESMO), Italy
Professor of Clinical Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, Gray Laboratories
University of Oxford
Former Alternate Patient member of the
EMA Committee on Advanced Therapies (CAT)
Patient Advocate, Belgium
Data Analytics Specialist
Google Cloud, Switzerland
Senior Director, Business Partnerships
Within3
Vice President - Global Medical Strategy
Monocl